Tyra Biosciences Inc (TYRA) Stock Price, Quote & News

Company Profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with met...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 728 4760

Website: tyra.bio

Address:

2656 State Street, Carlsbad, United States

dmeph Sep. 16 at 1:57 PM

$TYRA cooling off and preparing for the fall

0 · Reply

topstockalerts Sep. 14 at 8:39 PM

$TYRA I looked away and it was higher

0 · Reply

PensionPulse Sep. 14 at 3:31 PM

$TYRA Notice the double bottom around $22? Thank you very much!😁

0 · Reply

flychicken1991 Sep. 14 at 10:53 AM

$TYRA Negative (89%): TYRA's stock price is likely to face immediate downward pressure because investors must absorb 9,079,000 newly offered common shares plus pre-funded warrants covering another 9,078,529 shares... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/7f24ed734c52561f/tyra-tyra-announces-pricing-of-400-million-underwritten-offering-of-comm?utm_source=stocktwits&utm_medium=story_url

0 · Reply

Market_Pulse_Report Sep. 10 at 12:25 PM

$TYRA

0 · Reply

Monkey7779192 Sep. 9 at 10:57 PM

$TYRA lesson learned. Youd lose all your money trading xoin flip readouts. I thought this had great set up. Analyst pumping it, large call OI. Chart looking good ln 1 year tf. But nah. Still B.S.

1 · Reply

Market_Pulse_Report Sep. 9 at 9:27 PM

$TYRA Enjoy this video I just posted, I went over all of the financials!!! Really good overview! https://youtu.be/dkyWu2ISM0A

0 · Reply

BioRich Sep. 9 at 5:59 PM

$TYRA Congrats to those that remained believers and added when this dropped this morning.

1 · Reply

theSnip3r Sep. 9 at 4:49 PM

$TYRA this bounced hard wow wish i got some here

0 · Reply

kylevallans Sep. 9 at 1:50 PM

Premarket Losers $GCDT -32.46% $TYRA -27.95% $NNOX -20.49% $TTAN -17.57% $GOSS -17.12% View this Premarket Losers Scanner here. https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading

0 · Reply

Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer

2026-09-22T10:15:55.000Z - 8 hours ago

Tyra Biosciences price target lowered to $29 from $30 at H.C. Wainwright

2026-09-14T10:50:21.000Z - 8 days ago

Tyra Biosciences prices $400M underwritten offering of common stock and warrants

Sep 14, 2026, 6:45 AM EDT - 8 days ago

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2026-09-14T10:10:42.000Z - 8 days ago

Tyra Biosciences files automatic mixed securities shelf

2026-09-10T10:10:31.000Z - 12 days ago

Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright

Sep 9, 2026, 1:00 PM EDT - 13 days ago

Tyra Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 10:44 AM EDT - 13 days ago

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

2026-09-09T12:50:24.000Z - 13 days ago

Tyra data ‘lukewarm, but not program terminating,’ says Jones

Sep 9, 2026, 8:00 AM EDT - 13 days ago

Tyra Biosciences Transcript: Study result

Sep 9, 2026, 8:00 AM EDT - 13 days ago

Tyra Biosciences Press release: Study result

Sep 9, 2026, 8:00 AM EDT - 13 days ago

Tyra Biosciences Slides: Study result

2026-09-09T11:05:31.000Z - 13 days ago

Tyra Biosciences reports results from Phase 2 study of SURF302

Sep 9, 2026, 7:00 AM EDT - 13 days ago

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

Sep 9, 2026, 7:00 AM EDT - 13 days ago

Tyra Biosciences Slides: Corporate presentation

Sep 8, 2026, 4:05 PM EDT - 13 days ago

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

Sep 4, 2026, 8:00 AM EDT - 18 days ago

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

2026-08-11T12:55:31.000Z - 6 weeks ago

Tyra Biosciences price target lowered to $39 from $42 at BofA

2026-08-05T19:16:00.000Z - 6 weeks ago

Tyra Biosciences price target lowered to $42 from $44 at Jefferies

2026-08-05T16:40:25.000Z - 6 weeks ago

Tyra Biosciences delayed cancer data by one month, says JonesResearch

2026-08-05T16:40:21.000Z - 6 weeks ago

Tyra Biosciences falls 20% after pushing data readout to September from August

2026-08-04T20:30:34.000Z - 6 weeks ago

Tyra Biosciences reports Q2 EPS (69c), consensus (64c)

Aug 4, 2026, 4:05 PM EDT - 6 weeks ago

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Aug 4, 2026, 4:00 PM EDT - 6 weeks ago

Tyra Biosciences Earnings release: Q2 2026

Aug 4, 2026, 4:00 PM EDT - 6 weeks ago

Tyra Biosciences Quarterly report: Q2 2026

2026-06-17T11:55:07.000Z - 3 months ago

Tyra Biosciences assumed with an Outperform at Oppenheimer

2026-06-17T11:12:23.000Z - 3 months ago

Tyra Biosciences initiated with a Buy at JonesResearch

2026-06-10T10:36:56.000Z - 3 months ago

Tyra Biosciences price target raised to $42 from $37 at BofA

Jun 3, 2026, 3:45 PM EDT - 3 months ago

Tyra Biosciences Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 2:00 PM EDT - 3 months ago

Tyra Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 8:00 AM EDT - 4 months ago

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

2026-05-19T10:11:49.000Z - 4 months ago

Tyra Biosciences initiated with a Peer Perform at Wolfe Research

May 13, 2026, 1:40 PM EDT - 4 months ago

Tyra Biosciences Transcript: Bank of America Global Healthcare Conference 2026

2026-05-13T16:58:10.000Z - 4 months ago

Tyra Biosciences reports Q1 EPS (64c), consensus (59c)

May 13, 2026, 8:00 AM EDT - 4 months ago

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

May 13, 2026, 8:00 AM EDT - 4 months ago

Tyra Biosciences Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 4 months ago

Tyra Biosciences Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 4 months ago

Tyra Biosciences to Participate in Upcoming Investor Conferences

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Tyra Biosciences Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Tyra Biosciences Proxy statement: Proxy filing

Mar 4, 2026, 11:50 AM EST - 6 months ago

Tyra Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:05 PM EST - 6 months ago

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Mar 2, 2026, 3:00 PM EST - 6 months ago

Tyra Biosciences Annual report: Q4 2025

Mar 2, 2026, 3:00 PM EST - 6 months ago

Tyra Biosciences Earnings release: Q4 2025

Feb 26, 2026, 12:00 PM EST - 6 months ago

Tyra Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 5:30 PM EST - 7 months ago

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Dec 1, 2025, 8:00 AM EST - 9 months ago

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

Nov 19, 2025, 11:00 AM EST - 10 months ago

Tyra Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 10 months ago

Tyra Biosciences Announces Participation at Upcoming Investor Events

Nov 5, 2025, 4:05 PM EST - 10 months ago

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

Nov 5, 2025, 7:00 AM EST - 10 months ago

Tyra Biosciences Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Tyra Biosciences Quarterly report: Q3 2025

Sep 10, 2025, 9:00 AM EDT - 1 year ago

Tyra Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 11:00 AM EDT - 1 year ago

Tyra Biosciences Transcript: H.C.Wainwright @ Home Fireside Chat

Aug 21, 2025, 8:00 AM EDT - 1 year ago

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Tyra Biosciences Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Tyra Biosciences Earnings release: Q2 2025

Jul 25, 2025, 11:00 AM EDT - 1 year ago

Tyra Biosciences Transcript: Status Update

Jul 21, 2025, 4:05 PM EDT - 1 year ago

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

Jul 8, 2025, 4:05 PM EDT - 1 year ago

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

May 13, 2025, 8:15 PM EDT - 1 year ago

Tyra Biosciences Transcript: BofA Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 8, 2025, 4:05 PM EDT - 1 year ago

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025, 4:00 PM EDT - 1 year ago

Tyra Biosciences Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Tyra Biosciences Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Tyra Biosciences Registration statement: Registration Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Tyra Biosciences Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Tyra Biosciences Proxy statement: Proxy Filing

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tyra Biosciences Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tyra Biosciences Earnings release: Q4 2024

Mar 3, 2025, 9:50 AM EST - 1 year ago

Tyra Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 12, 2025, 2:00 PM EST - 1 year ago

Tyra Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 4:05 PM EST - 1 year ago

Tyra Biosciences to Present at Upcoming Investor Conferences

Jan 22, 2025, 8:00 AM EST - 1 year ago

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Jan 10, 2025, 8:00 AM EST - 1 year ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Dec 4, 2024, 10:30 AM EST - 1 year ago

Tyra Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 9:00 AM EST - 1 year ago

Tyra Biosciences Transcript: Jefferies London Healthcare Conference 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Nov 7, 2024, 4:00 PM EST - 1 year ago

Tyra Biosciences Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Tyra Biosciences Earnings release: Q3 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Tyra Biosciences Transcript: Study Update

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Tyra Biosciences Press release: Study Update

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Tyra Biosciences Slides: Study Update

Oct 24, 2024, 6:21 PM EDT - 1 year ago

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Sep 17, 2024, 9:45 AM EDT - 2 years ago

Tyra Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 2 years ago

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 2 years ago

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Sep 2, 2024, 11:00 AM EDT - 2 years ago

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Aug 27, 2024, 11:00 AM EDT - 2 years ago

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

dmeph Sep. 16 at 1:57 PM

$TYRA cooling off and preparing for the fall

0 · Reply

topstockalerts Sep. 14 at 8:39 PM

$TYRA I looked away and it was higher

0 · Reply

PensionPulse Sep. 14 at 3:31 PM

$TYRA Notice the double bottom around $22? Thank you very much!😁

0 · Reply

flychicken1991 Sep. 14 at 10:53 AM

0 · Reply

Market_Pulse_Report Sep. 10 at 12:25 PM

$TYRA

0 · Reply

Monkey7779192 Sep. 9 at 10:57 PM

$TYRA lesson learned. Youd lose all your money trading xoin flip readouts. I thought this had great set up. Analyst pumping it, large call OI. Chart looking good ln 1 year tf. But nah. Still B.S.

1 · Reply

Market_Pulse_Report Sep. 9 at 9:27 PM

$TYRA Enjoy this video I just posted, I went over all of the financials!!! Really good overview! https://youtu.be/dkyWu2ISM0A

0 · Reply

BioRich Sep. 9 at 5:59 PM

$TYRA Congrats to those that remained believers and added when this dropped this morning.

1 · Reply

theSnip3r Sep. 9 at 4:49 PM

$TYRA this bounced hard wow wish i got some here

0 · Reply

kylevallans Sep. 9 at 1:50 PM

Premarket Losers $GCDT -32.46% $TYRA -27.95% $NNOX -20.49% $TTAN -17.57% $GOSS -17.12% View this Premarket Losers Scanner here. https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading

0 · Reply

DonCorleone77 Sep. 9 at 1:14 PM

$CASY $SAIL $TYRA PRE-MARKET MOVERS: Currently Higher After Earnings: - Oddity (ODD) up 33.7% - J.Jill (JILL) up 10.9% - Signet Jewelers (SIG) up 16.1% - Caleres (CAL) up 7.2% - InnovAge (INNV) up 9.6% - Jersey Mike's Subs (JMKE) up 2.5% Currently Lower After Earnings: - ServiceTitan (TTAN) down 19.1% - Casey's General Store (CASY) down 11.6% - SailPoint (SAIL) down 6.5% - Chewy (CHWY) down 3.9%. Currently Also Lower: - Tyra Biosciences (TYRA) down 28.5% after reporting initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer

0 · Reply

briefingcom Sep. 9 at 12:43 PM

$TYRA: Tyra Biosciences (-33.2%) is plunging after initial Phase 2 SURF302 data delivered a 57% 3-month complete response rate in the full 60 mg cohort, falling short of the ~70% benchmark investors were looking for. Favorable safety and a 79% ORR offered positives, but efficacy and trial-design questions are weighing on shares.

0 · Reply

Windy007 Sep. 9 at 12:33 PM

$TYRA BofA Tyra announced arguably mixed initial results from its phase 2 SURF302 study of dabogratinib (dabo) in IR NMIBC The overall 57% 3 mos CR rate missed the 70% success benchmark, though safety came in better than expected While we see a path forward, uncertainties around dose/ design is likely to remain an overhang for now. Maintain Buy, $39 PO

0 · Reply

STACKD0E Sep. 9 at 12:20 PM

$TYRA $PYXS $PRZO 👁

1 · Reply

OpenOutcrier Sep. 9 at 12:20 PM

$TYRA (-34.3% pre) Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib https://ooc.bz/l/113616

0 · Reply

WantedToRetireEarly Sep. 9 at 12:11 PM

$CGON $TYRA $URGN $IBRX

0 · Reply

Rogerrabbit Sep. 9 at 12:10 PM

$TYRA 😎🏖 No, the 70% target was not reached for the 3-month complete response rate in the full 60 mg cohort. That likely explains a significant part of today’s negative market reaction. However, the results are far from bad: a 79% ORR, 64% best overall CR, and a very favorable safety profile remain clinically meaningful, and TYRA believes the data support its planned Phase 3 strategy. My take: the results are moderately bullish rather than a home run. The main issue is that the market was probably expecting a ≥70% 3-month CR rate. My take: the results are moderately bullish rather than a home run. The main issue is that the market was probably expecting a ≥70% 3-month CR rate.

0 · Reply

SannieVerraderlijk Sep. 9 at 11:39 AM

$TYRA Underwhelmed, can we pump my $RLMD bags now?

0 · Reply

notreload_ai Sep. 9 at 11:36 AM

$TYRA 60 mg data showed 57% 3-month CR vs. the ~70% bar. Safety was clean. Small n, extra 70 mg work, and positioning drove the sell-off. https://notreload.xyz/xy/tyra-surf302-data-safety-held-efficacy-missed-street-bar/

0 · Reply

HumblKing Sep. 9 at 11:05 AM

$TYRA bad https://www.prnewswire.com/news-releases/tyra-biosciences-reports-initial-phase-2-surf302-results-supporting-the-first-potential-oral-innovation-in-lg-ir-nmibc-with-dabogratinib-302872937.html

0 · Reply

Monkey7779192 Sep. 8 at 9:00 PM

$TYRA So get out now or what?

0 · Reply

Monkey7779192 Sep. 8 at 4:50 PM

$TYRA How we feeling about the readout tomorrow?

2 · Reply

Market Cap	1.54B
Revenue (ttm)	0.00
Net Income (ttm)	-119.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	366,354
Avg Vol	845,128
Day's Range	N/A - N/A
Shares Out	59.68M
Stochastic %K	84%
Beta	0.73
Analysts	Strong Sell
Price Target	$48.45